// App-Quantinova.ai

591 : 4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients.

Researchers

Presenter

  • Peter A. Fasching

Principal Investigators

  • Tanja N Fehm

  • Peyman Hadji

  • Julia Kreuzeder

  • Michael P Lux

  • Wolfgang Janni

  • Andreas Schneeweiss

  • Erik Belleville

  • Thomas Decker

  • Eva-Maria Grischke

  • Daniel Sickert

  • Michael Pugia

  • Katja Friedrich

  • Mark Matzas

  • Diana Lueftner

  • Matthias W. Beckmann

  • Hans Tesch

  • Lothar Haeberle

  • Mathias Muth

Medical Centers

  • Department of Hematology, Oncology and Tumor Immunology, Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany

  • University of Tubingen, Tubingen, Germany

  • Department of Obstetrics and Gynaecology, University Breast Centre for Franconia, Erlangen, Germany

  • Department of Obstetrics and Gynecology, University Erlangen, Erlangen, Germany

  • Healthcare Sector, Erlangen, Germany

  • Department of Gynecology and Obstetrics, University Hospital Dresden, Dresden, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • Department of Gynecology and Obstetrics, Duesseldorf, GermanyClinsol Gmbh & Co Kg, Wuerzburg, GermanyCorporate Technology, Erlangen, Germany

  • Onkologie Ravensburg, Ravensburg, Germany

  • Siemens AG, Erlangen, Germany

  • Novartis Pharma GmbH, Nuernberg, Germany

  • Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt/Main, Germany

  • Siemens Healthcare Diagnostics, Elkhart, IN

  • University Hospital of Giessen and Marburg GmbH, Marburg, Marburg, Germany

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

  • erb-b2 receptor tyrosine kinase 2

  • Human epidermal growth factor receptor 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • Everolimus

  • Exemestane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01626222

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved